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Abstract 
Mounting evidence suggests that aberrations in immune-inflammatory pathways 
contribute to the pathophysiology of major depressive disorder (MDD), and individuals 
with MDD may have elevated levels of predominantly pro-inflammatory cytokines and 
C-reactive protein. In addition, previous meta-analyses suggest that antidepressant drug 
treatment may decrease peripheral levels of interleukin-1 beta (IL-1β) and IL-6. Recently, 
several new studies examining the effect of antidepressants on these cytokines have been 
published, and so we performed an up-dated meta-analysis of studies that measured 
peripheral levels of cytokines and chemokines during antidepressant treatment in patients 
with MDD. The PubMed/MEDLINE, EMBASE, and PsycInfo databases were searched 
from inception through March 9th, 2017. Forty-five studies met inclusion criteria 
(N=1517). Peripheral levels of IL-6, tumor necrosis factor alpha (TNF-α), IL-1β, IL-10, 
IL-2, IL-4, interferon-γ, IL-8, the C-C motif ligand 2 chemokine (CCL-2), CCL-3, IL-1 
receptor antagonist, IL-13, IL-17, IL-5, IL-7, and the soluble IL-2 receptor were measured 
in at least three datasets and thus were meta-analyzed. Antidepressant treatment 
significantly decreased peripheral levels of IL-6 (Hedges g = -0.454, P < 0.001), TNF-α 
(g = -0.202, P = 0.015), IL-10 (g = -0.566, P = 0.012), and CCL-2 (g = -1.502, P = 0.006).  
These findings indicate that antidepressants decrease several markers of peripheral 
inflammation. However, this meta-analysis did not provide evidence that reductions in 
peripheral inflammation are associated with antidepressant treatment response although 
few studies provided separate data for treatment responders and non-responders. 
Keywords: depression; meta-analysis; antidepressant; cytokines; chemokines; 
inflammation 
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Introduction 
Accumulating evidence indicates that activation of immune-inflammatory pathways may 
contribute to the development of major depressive disorder (MDD) in at least a sub-set 
of patients [1,2]. In particular, activation of cell-mediated immunity (CMI) may play a 
significant role in the biology of MDD [3]. Cytokines and chemokines are key regulators 
of immune function, with different roles (for example, some of these mediators are 
predominantly pro-inflammatory, whereas others are mainly anti-inflammatory) [4,5]. A 
recent meta-analysis of 82 studies found elevated peripheral levels of interleukin-6 (IL-
6), tumor necrosis factor (TNF)-alpha, IL-10, the soluble IL-2 receptor, C-C chemokine 
ligand 2 (CCL-2), IL-13, IL-18, IL-12, the IL-1 receptor antagonist, and the soluble TNF 
receptor 2 in patients with MDD compared to healthy controls [6]. 
 Most antidepressants are thought to primarily act by increasing or otherwise 
modulating monoamine function [7]. However, emerging evidence suggests that immune 
mechanisms may contribute to the therapeutic benefits of some of these drugs [8]. For 
example, a study found that selective serotonin reuptake inhibitors (SSRIs) but not 
venlafaxine inhibited lipopolysaccharide (LPS)-stimulated microglia in vitro [9]. A 
previous meta-analysis provided evidence that antidepressant drugs may decrease IL-1β 
levels in patients with MDD [10], whereas another meta-analysis indicated that 
antidepressants decrease IL-6 levels [11]. Heterogeneity across studies was high in these 
estimates. Since these meta-analyses were published, new studies have appeared in the 
literature [12,13]. In addition, a few studies suggest that peripheral immune activation 
may predict treatment non-response [12,14]. 
 This present systematic review and meta-analysis aims to reassess available 
evidence of the effects of antidepressants on peripheral levels of cytokines and 
chemokines in individuals with MDD. In addition, we sought to explore potential sources 
Köhler et al. Antidepressant treatment and inflammation 
 
5 
 
of heterogeneity across studies and to investigate whether antidepressant-related changes 
in cytokine/chemokine levels differed between treatment responders and non-responders.  
Methods 
This study comprised a within-group meta-analysis of studies that compared peripheral 
levels of cytokines and chemokines in participants with MDD at baseline and after 
treatment with an approved antidepressant. We complied with the Preferred Reported 
Items for Systematic Reviews and Meta-analysis (PRISMA) statement [15]. The 
literature search, title/abstract screening, final decision on eligibility after full-text-
review, and data extraction were independently performed by two investigators (THF and 
NQA). Disagreements were resolved through consensus. If a consensus could not be 
achieved the decision was made independently by a third investigator (CAK). 
Search Strategy 
A systematic search was conducted in the PubMed/MEDLINE, EMBASE and PsycInfo 
databases from inception up until March 9tth, 2017. The detailed search strings used in 
this review are presented in the supplementary online material that accompanies the 
online version of this article. This search strategy was augmented by tracking the citation 
lists of included articles in Google Scholar [16]. 
Study selection 
We included original peer-reviewed articles published in any language. Eligible studies 
had to measure peripheral cytokine or chemokine levels in adult subjects (age ≥ 18 years 
old) who met either DSM [17] or ICD [18] criteria for MDD. The following exclusion 
criteria were adopted: (1) studies in which participants had medical and/or psychiatric 
comorbidities (except current smoking); (2) studies which included pregnant women or 
women in the postpartum period; (3) case reports or case series (N < 10); (4) studies that 
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assayed the immune variables in specimens/tissues other than blood(e.g. CSF); (5) studies 
in animals or assessing cytokine/chemokine production in vitro; and (6) studies which 
included other interventions (e.g. exercise) unless data for patients treated with 
antidepressants were separately provided. The authors of meeting abstracts which met 
inclusion criteria were contacted by e-mail to provide data for analysis (no additional data 
were provided). 
Data extraction 
For each immune mediator, we extracted means, variance estimates [standard deviation 
(SD), standard error of the mean (SEM) or 95% confidence interval (CI)] and sample 
sizes for of each study. In studies that provided median ± IQR or median ± range, we 
estimated the mean ± SD following a standard procedure [19]. For purposes of data 
extraction, we considered cytokine/chemokine levels at baseline and at the time during 
treatment when the largest number of participants were included in analysis (follow-up 
time ≥ 4 weeks). We also extracted the following data whenever available: (1) first author; 
(2) publication year; (4) gender distribution (% females); (5) mean age and body mass 
index (BMI); (6) mean illness duration (years); (7) treatment status (drug-free during 
assessment and/or treatment-naïve); (8) measurement of depressive symptoms at baseline 
and endpoint; (9) response rates (defined as the percentage of participants who achieved 
a 50% reduction in baseline depression scores at endpoint); (9) follow-up time (weeks); 
(10) studies in which a single antidepressant class was used vs. those in which agents 
from more than one antidepressant class were used; (11) frequency of melancholic and 
atypical depression in the sample; and (12) current smokers (%). For studies that included 
healthy controls (HCs) we also extracted the following data in these participants: (1) 
sample size and (2) chemokine/cytokine levels.  
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Methodological quality assessment of includes studies 
Seven parameters were used to estimate the methodological quality of included studies: 
(1) enrolled at least 40 participants with MDD at baseline (1=Y; 0=No); (2) attrition rate 
≤ 20% (1=Yes; 0=No); (3) provided treatment response rates (1=Y; 0=No); (4) contrasted 
cytokine/chemokine levels between responders versus non-responders (1=Y; 0=No); (5) 
a washout period was conducted prior to trial initiation or otherwise participants were 
treatment-naïve (1=Y; 0=No); (6) time of sample collection was reported (e.g. morning 
vs. evening) (1=Y; 0=No); and (7) the manufacturer of the test was reported (and test 
parameters could be verified at the proper website) or other test parameters were provided 
(i.e. detection limit and coefficient of variation was reported).   
Statistical analysis 
Because studies used different measurement methods, we estimated a standardized mean 
difference (Hedges’s g) and 95% confidence intervals (Cis) for each immune mediator, 
which provides an unbiased effect size (ES) adjusted for small sample sizes [20]. We 
assessed the heterogeneity across studies using the Cochran Q test, a weighted sum of the 
squares of the deviations of individual study ES estimates from the overall estimate. In 
addition, heterogeneity across studies was quantified with the I2 statistic, which in brief 
indicates the percentage of total variation across several studies due to heterogeneity, and 
it is considered large when ≥ 50% [21]. We anticipated a high degree of heterogeneity. 
Therefore, we pooled ES using a random-effects model according to the DerSimonian 
and Laird, using the inverse variance method to estimate heterogeneity [22]. Meta-
analyses were carried only for mediators with at least 3 individual datasets. Random-
effects modelling assumes a genuine diversity across studies and incorporates a between-
study variance into the calculations [20]. An ES of 0.2 was considered low, 0.5 moderate, 
and 0.8 large [23].  
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 We computed composite measures to provide an indication of the profiles of 
peripheral immune activation involved in MDD (i.e. T Helper (TH1), TH2, regulatory T 
cells (TRegs), and macrophage polarized M1 phenotype responses). To this end, we 
averaged the ES estimates from each study which contributed with a mediator included 
in the a priori defined biosignatures. The rationale for the estimation of each aggregate 
measure is provided in the Supplementary online material that accompanies to online 
version of this article (Supplementary Table S1 describes the mediators and number of 
studies that contributed to each composite ES estimate, available online). 
 Studies with statistically non-significant (i.e. negative) results are less likely to be 
published than studies with significant results [24,25]. To assess publication bias, we 
inspected a funnel plot graph for asymmetry, and calculated the Egger’s regression test 
for funnel plot asymmetry [26]. Evidence of small-study effects (indicative of publication 
bias) was considered when the P-value of the Egger’s test was < 0.1 and the ES of the 
largest study was more conservative or changed direction when compared with the overall 
ES estimate (funnel plots of ES estimates in which evidence of publication bias was 
observed are presented in Supplementary Figures S12-S14, available online) [25]. The 
trim-and-fill procedure was used to estimate the ES adjusting to publication bias [27], 
while the fail-safe N (i.e. the file drawer) statistic was used to determine how many 
additional studies would be necessary to turn significant ES non-significant [28].  
  We explored potential sources of heterogeneity across studies in each mediator, 
using either subgroup (if there were at least 3 studies in each subgroup) or random-effects 
meta-regression analyses (if there were at least 5 studies with available moderator data). 
We grouped studies in which response rates were above the median value for a specific 
immune mediator and contrasted them with studies in which response rates were below 
the median value. Fewer datasets often provide underpowered and unreliable estimates 
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[29]. The following variables were considered in meta-regression analyses: sample size; 
mean age; mean BMI; gender distribution (% Females); % of current smokers; response 
rates (%); changes in depressive symptoms from baseline (normalized to the threshold 
for severe depression for each rating scale); mean illness duration in years; treatment 
response rate (%). Studies were weighted in such a way that investigations with more 
precise parameters (indicated by sample size and 95% CIs) had more influence in meta-
regression analyses [29]. For statistically significant ES estimates we performed 
sensitivity analyses in which we excluded each study from analyses to verify whether a 
single study turned results non-significant or otherwise changed the direction of the ES. 
In addition, a cumulative meta-analysis was performed for immune mediators with 
significant ES estimates and at least 10 datasets. These analyses address the influence of 
new studies on prior pooled results. For these analyses, individual data sets were sorted 
in chronological order. The earliest available study was included in the analysis first. At 
each subsequent step of the cumulative meta-analysis, one more study was included in 
the analysis, and the summary ES and 95 % CI were recalculated. The ‘Proteus 
phenomenon’ refers to the situation in which the first published studies are often the most 
biased toward inflated effect sizes (i.e. the winner’s curse); subsequent replication studies 
tend to be less biased toward the extreme, often finding evidence of smaller effects or 
even contradicting the findings of initial studies. Thus, cumulative meta-analyses allow 
the appreciation of these phenomena. 
All analyses were conducted in Stata MP software version 14.0 (Stata-Corp, 
College Station, TX, USA) using the metan package. Statistical significance was 
considered at an alpha level of 0.05. 
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Results 
Study selection 
Following removal of duplicates, the title/abstracts of 5521 unique references were 
screened for eligibility. A total of 5102 references were excluded, while 419 full-texts 
were retrieved and screened for eligibility. Of those articles, 374 were excluded (see 
Supplementary Table S2 that accompanies to online version of this article for reasons for 
exclusion). Finally, 45 original studies met inclusion criteria. Figure 1 provides the 
PRISMA flowchart for study selection.  
<Insert Figure 1 here> 
Characteristics and methodological quality of included studies 
A total of 45 studies were included (N=1517). The mean follow-up was 7.6 weeks 
(SD=3.3; range=4‒20). Twenty-one studies (46.7%) included only SSRIs, while 5 
(11.1%) investigations included only SNRIs and nineteen (42.2%) included 
‘miscellaneous’ antidepressants. Thirteen (28.9%) contrasted cytokine/chemokine levels 
between treatment responders and non-responders. Characteristics of included studies are 
provided in Supplementary Table S3 (available online).    
Quality scores of the included studies ranged from 2 to 7 (median: 4). The scores 
of each study are presented in supplementary Table S3 (available online).   
Interleukin-6 
Interleukin-6 (IL-6) was measured in 24 studies (N=722). Antidepressant treatment 
significantly reduced IL-6 levels with a moderate ES (Hedge’s g = -0.454) (Table 1; 
Figure 2A). Heterogeneity was large (I2 = 84.7%). There was no evidence of publication 
bias. In meta-regression analysis, mean difference in depressive symptom scores was a 
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significant moderator (the higher the difference in depressive symptom scores, the lower 
the difference in IL-6 levels between endpoint and baseline) (Supplementary Table S4, 
available online). Heterogeneity was higher in SSRI studies compared to studies using 
‘miscellaneous’ antidepressants (Supplementary Table S5, available online). Finally, IL-
6 levels decreased in studies which sampled this cytokine from plasma, but not in those 
in which IL-6 was sampled from serum (Table S5, available online). In sensitivity 
analysis, the exclusion of any single study one-at-a-time did not alter de direction or 
statistical significance of the ES (Figure S15). In cumulative meta-analysis this ES 
estimate has been consistent since 2005 (Figure S19, available online). 
<Please insert Table 1 here> 
<Please insert Figure 2 here> 
Tumor necrosis factor-alpha (TNF-α) 
Levels of TNF-α were significantly lower after antidepressant treatment (23 studies; 
N=797). The ES estimate was small (Hedge’s g = -0.202; P=0.015) (Table 1; Figure 2B). 
There was evidence of publication bias, but the ES remained small and significant after 
adjustment with the trim-and-fill procedure. Heterogeneity was large (I2 = 80.0%). Mean 
baseline depressive symptoms were associated with lower differences in TNF-α between 
endpoint and baseline in meta-regression analysis (Table S4, available online). Subgroup 
analyses indicated that heterogeneity was lower in studies which used either SNRIs or 
‘miscellaneous’ antidepressants compared to SSRI studies (Table S5, available online). 
Levels of TNF-α significantly decreased in studies in which its levels were assayed with 
ELISA but not in those studies that used other types of assay (Table S5, available online), 
and levels decreased only in studies where treatment time was longer than the median 
(Table S5, available online). In addition, sensitivity analysis revealed that the individual 
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exclusion of two studies one-at-a-time rendered this ES non-significant (Figure S16, 
available online). Finally, the cumulative meta-analysis indicates that this ES estimate 
has not been consistent over time (Figure S20, available online).  
Interleukin-1 Beta (IL-1β) 
Levels of IL-1β were not significantly reduced after antidepressant drug treatment 
(Hedge’s g = -0.255; P=0.176; 15 studies; N=331; Figure 2C). There was no evidence of 
publication bias. Heterogeneity was large (I2 = 92.0%) (Table 1). In meta-regression 
analyses, the longer the mean follow-up time the larger the difference in IL-1β between 
endpoint and baseline (Table S4, available online). Subgroup analyses indicated that 
heterogeneity was significantly lower in studies using either ‘miscellaneous’ 
antidepressants or SNRIs compared to studies using SSRIs (Table S5, available online). 
In addition, heterogeneity was lower in studies in which IL-1β was sampled from plasma 
compared to studies in which this cytokine derived from serum (Table S5, available 
online).     
Interleukin-10 
Levels of IL-10 were measured in 10 studies (N=331), and were significantly reduced 
after antidepressant drug treatment (Hedge’s g = -0.566) (Figure 2D). However, there was 
evidence of small-study effects, but adjustment for publication bias with the trim-and-fill 
procedure did not change the ES (Table 1). In meta-regression analysis, the longer the 
mean follow-up time of the study the lower the difference in IL-10 levels between 
endpoint and baseline (Table S4, available online). In subgroup analyses, levels of IL-10 
significantly decreased with low heterogeneity in studies using miscellaneous 
antidepressants but not in studies using SSRIs, which had high heterogeneity. In addition, 
IL-10 decreased with low heterogeneity in studies which sampled this cytokine from 
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plasma but not in studies which sampled this cytokine from serum, which had high 
heterogeneity. IL-10 levels were found to be reduced in studies that used other assay types 
but not in those that used ELISA (Table S5, available online). Levels were also decreased 
only when treatment duration was above the median. Sensitivity analysis revealed one 
possible outlier [30] (Figure S17, available online), while the ES appears stable since 
2009 (Figure S21, available online).  
C-C motif ligand 2 chemokine (CCL-2)  
Levels of the chemokine CCL-2 were examined in five studies (N=163). Antidepressant 
drug treatment significantly reduced CCL-2 levels with a large ES estimate (Hedge’s g = 
-1.502) (Figure 2E). There was no evidence of small-study effects (Table 1), and the 
heterogeneity was large (I2 = 96.0%). Meta-regression analyses did not identify any 
moderator (Table S4, available online). Sensitivity analysis revealed that the exclusion of 
a single study one-at-a-time turned this ES non-significant (Figure S18, available online).  
Other immune variables 
Eleven additional immune variables (Interferon gamma-IFN-γ, IL-4, IL-2, IL-8, CCL-3, 
IL-1 receptor antagonist, IL-13, IL-17, IL-5, IL-7, and the soluble IL-2 receptor) were 
investigated in at least three studies, and were meta-analyzed. Overall, levels of these 
cytokine/chemokines were not significantly altered after antidepressant drug treatment 
(Table 1). The forest plots for these estimates are provided in the supplementary online 
material that accompanies the online version of this article (Figures S1 to S11, available 
online). Heterogeneity for these estimates was large (I2 between 64.2 to 95.5%), with the 
exception of the soluble IL-2 receptor where heterogeneity was low. 
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Composite scores 
Composite measures of cytokine/chemokine profiles suggestive of the activation of 
different immune cells were calculated. We found evidence that antidepressant drug 
treatment may lead to a significant reduction in cytokines/chemokines predominantly 
secreted by M1 macrophages (Hedge’s g = -0.35; P < 0.001), whereas 
cytokines/chemokines predominantly secreted by TH1, TH2, and TRegs were not 
significantly altered (Figure 3). 
<Please insert Figure 3 here> 
Treatment response 
Based on data provided by individual studies, we were able to contrast ES for changes in 
TNF-α and IL-6 levels between antidepressant treatment respondents vs. non-responders. 
These ES estimates were non-significant (TNF-α for responders: g=-0.346, k=8, P=0.115; 
TNF-α for non-responders: g=0.049, k=7, P=0.590; IL-6 for responders: g=-0.222, k=4, 
P=0.480; IL-6 for non-responders: g=-0.010, k=4, P=0.964). IL-1β levels were not altered 
in treatment responders (g=0.617, k=3, P=0.407), while peripheral levels of this cytokine 
for treatment non-responders from at least 3 independent datasets were not available. In 
addition, we could contrast baseline levels of TNF-α and IL-8 between responders and 
non-responders. There was no difference in the baseline levels of both cytokines (TNF-
α: Hedges’s g = 0.248, k=7, P=0.353; IL-8: Hedges’s g = -0.082; k=3; P= 0.595) in 
responders versus non-responders.  
 
 
 
 
Köhler et al. Antidepressant treatment and inflammation 
 
15 
 
Discussion 
This meta-analysis suggests that the pharmacological treatment of MDD is accompanied 
by a significant decrease in levels of IL-6, TNF-α, IL-10, and CCL-2. Previous meta-
analyses have found that antidepressant drug treatment may reduce TNF-α and IL-6 levels 
in individuals with MDD [10,11]. These previous studies provided effect size estimates 
for TNF-α, IL-1β, IL-6, and IL-10. In addition, similarly to the current meta-analysis, a 
high degree of heterogeneity was observed [10,11]. Furthermore, two recent meta-
analysis found different results regarding changes in peripheral levels immune mediators 
after antidepressant treatment [31,32]. One of this meta-analysis verified that 
antidepressant drug treatment decreased levels of IL-6, IL-10 and IL-12, and increased 
levels of IL-1β and IL-4 [32]. However, this meta-analysis included relatively few 
studies, and estimated ES through fixed-effects modelling, which can provide unreliable 
results when heterogeneity across studies is high [32,21]. The largest previous meta-
analysis synthesized data from 35 original studies [31]. Nevertheless, this effort included 
participants with bipolar depression, while non-pharmacological treatments for 
depression were also considered [31]. Due to the largest amount of data available, we 
were able to estimate effect sizes for 16 immune mediators. In addition, we could explore 
more potential sources of heterogeneity than has previously been possible.   
 Meta-analytic evidence suggests that IL-6, TNF-α, IL-10, the soluble IL-2 
receptor, CCL-2, IL-12, IL-13, IL-18, the IL-1 receptor antagonist, the soluble TNF 
receptor 2, and C-reactive protein levels are elevated in individuals with MDD compared 
to healthy controls [33,6,34].  We found that antidepressants significantly decreased 
peripheral levels of IL-6, IL-10, TNF-α, and CCL-2. Notwithstanding the fact that 
approved antidepressants are thought to primarily act via monoaminergic mechanisms, a 
compelling body of evidence indicates that an activation of neurotrophic mechanisms in 
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the brain may significantly contribute to the therapeutic effects of antidepressants [35]. 
Interestingly preclinical evidence indicates that peripheral inflammation may influence 
hippocampal plasticity via microglial activation [36]. In addition, IL-6 and TNF-α may 
reduce hippocampal synaptic plasticity [37]. Thus, our findings are consistent with the 
view that antidepressants may diminish peripheral inflammation and its impact on the 
brain [8] although our analysis indicate that these effects may not be consistently 
associated with treatment response. Previous evidence indicates that peripheral 
inflammation may be observed in a subset but not in all individuals with MDD [1]. In 
addition, a previous study suggests that individuals with MDD and higher peripheral 
inflammation may respond to the TNF-α antagonist infliximab, whereas in patients with 
MDD and lower levels of peripheral inflammation the effects of infliximab did not 
significantly differ from placebo [38]. Therefore, it is possible that the observed effects 
of standard antidepressants observed herein (i.e., an overall decrease in predominantly 
inflammatory cytokines and chemokines) may not be the main mechanism contributing 
to the therapeutic benefits of these drugs [39]. However, no antidepressant study included 
in this meta-analysis a priori stratified participants with lower versus higher levels of pro-
inflammatory cytokines at baseline. In addition, both baseline as well as differences in 
levels of immune mediators were not been consistently provided across included studies 
as a function of treatment response.   
 A previous meta-analysis found that levels of TNF-α decreased in treatment 
responders but not in treatment non-responders [31]. In addition, it was suggested that 
baseline inflammation may predict antidepressant treatment response. However, this 
meta-analysis included several treatments other than antidepressant drugs, as well as 
participants with bipolar depression, and also included studies in which part of the sample 
had significant baseline comorbidities [31]. The current meta-analysis avoids these 
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potential confounders and includes more studies and participants. We found that although 
antidepressants may decrease TNF-α levels, these results should be interpreted cautiously 
due to the high heterogeneity across studies and the fact that sensitivity analysis indicated 
that some individual studies might have biased the overall ES estimate. In addition, we 
found no evidence that changes in peripheral levels of TNF-α significantly differed as a 
function of antidepressant treatment response. Furthermore, baseline TNF-α did not differ 
when antidepressant treatment responders were compared to non-responders. Finally, 
although antidepressants significantly decreased IL-6 levels, this effect did not 
significantly differ as a function of treatment response. 
     It has been postulated that the trafficking and redistribution of pro-inflammatory 
monocytes to t he brain may interact and activate microglial cells in ways that contribute 
to the pathophysiology of MDD [40]. Interestingly evidence indicates that TNF-α, IL-6, 
and CCL-2 may be predominantly secreted by M1 polarized macrophages albeit not 
selectively [41]. In addition, an emerging body of preclinical investigation suggests that 
SSRIs may decrease the secretion of inflammatory mediators by lipopolysaccharide-
stimulated microglial cells [42,9]. Thus, our results are in agreement with these 
experimental data although we found no conclusive evidence to demonstrate a differential 
impact of different classes of antidepressants upon peripheral immune activation. 
 We found evidence that antidepressants may decrease peripheral levels of the 
chemokine CCL-2. This chemokine is predominantly pro-inflammatory and has been 
implicated in the chemotaxis of peripheral monocytes to the brain [43]. The inhibition of 
the traffic of peripheral monocytes to the brain may constitute a promising novel 
therapeutic mechanism for MDD [44]. However, these results should be cautiously 
interpreted due to the limited number of available studies and by the fact that this ES did 
not survive sensitivity analysis. 
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 IL-10 is predominantly secreted by regulatory T cells (TRegs) and exerts mainly 
an anti-inflammatory effect [45]. It has been suggested that a 'compensatory 
(anti)inflammatory reflex system' (CIRS) may operate in MDD [46]. This system has 
been hypothesized to play a counter-regulatory (i.e. homeostatic) role in the context of 
peripheral inflammation. We found that antidepressants may reduce IL-10 levels in 
individuals with MDD. Thus, it is possible in theory that this effect may occur secondarily 
to an overall reduction of peripheral inflammation promoted by antidepressants.  
Strengths and Limitations 
 The main strength of this meta-analysis was the inclusion of the largest amount of 
data currently available, and the proper exploration of potential sources of heterogeneity. 
However, some potential sources of heterogeneity could not be explored due the lack of 
data reported across studies. For example, body mass index appear may influence both 
antidepressant treatment response [47] and peripheral inflammation [48]. In meta-
regression analysis, mean BMI did not significantly moderate changes in peripheral IL-
6, TNF-α, IL-1β, IFN-γ, and IL-10 levels after antidepressant treatment. However, 
included studies did not provide data to reliably control for this potential moderator for 
other cytokines/chemokines included in our analysis. Furthermore, our meta-regression 
analyses suggest that antidepressant-related differences in TNF-α levels were not 
moderated by % of current smokers. Nevertheless, these results should be cautiously 
interpreted because relatively few studies provided data on these potential moderators, 
and an accumulating body of evidence suggests that obesity and smoking may contribute 
to peripheral inflammation in patients with MDD [49-52]. Second, the methodological 
quality of included studies in this meta-analysis significantly varied. Third, we could not 
contrast differences in cytokine/chemokine levels after antidepressant treatment in 
individuals with melancholic and atypical depression (due to lack of data) although 
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evidence suggests that peripheral immune activation may differ in these depression 
subtypes [53]. Finally, differences in the standardization of assays across different 
laboratories as well as technical challenges to assay certain mediators (e.g. IL-2 and IFN-
γ) may have contributed to the heterogeneity of findings [54].  
 
Conclusion 
In summary, this meta-analysis showed that, overall, antidepressants decreased peripheral 
levels of IL-6, TNF-α, IL-10, and CCL-2. This meta-analysis suggests that 
antidepressants may decrease peripheral inflammation. However, this effect did not 
appear to consistently differ between responders and non-responders. In addition, 
baseline TNF-α levels did not predict antidepressant treatment response. Future studies 
should contrast peripheral cytokine/chemokine levels between responders and non-
responders. In addition, an individual patient meta-analysis in which participants are 
stratified according to the degree of baseline inflammation could represent a next step to 
investigate the hypothesis that antidepressants may be more efficacious for patients with 
lower peripheral inflammation, whereas anti-inflammatory agents may be promising 
strategy for those patients with higher immune activation [1,39]. Finally, other 
antidepressant treatment modalities with proven efficacy like electroconvulsive therapy 
(ECT) may also impact peripheral immune activation notwithstanding evidence remains 
limited [55,56]. Therefore, future studies may investigate whether cytokines/chemokines 
may serve as peripheral biomarkers of treatment response considering the new framework 
of precision psychiatry[57].  
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FIGURE LEGENDS 
Figure 1. PRISMA flowchart of study selection. 
Figure 2. Forest plots of studies which measured changes in peripheral (A) IL-6 (B) TNF-
α (C) IL-1β (D) IL-10 or (E) CCL-2 in individuals with MDD after antidepressant 
therapy. Effect size estimates are presented as Hedges’s g with 95% confidence intervals 
(CIs). Square sizes are proportional to the ES of each study. References are presented in 
the Supplementary online material. 
Figure 3. Effect size estimates in Hedges’s g (with 95% CI) of composite measures 
indicative of cytokine/chemokine profiles related to the activation of T Helper (TH) 1, 
TH2, Regulatory T cells (TReg), and M1 polarized macrophages. The number of datasets 
(k) included in each estimate is also depicted.  
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